Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07664527 · ClinicalTrials.gov registry record · Phase 4
Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT07664527: Clinical Trial Phase 4 study, sponsored by University of Wisconsin, Madison.
NCT07664527 is a Phase 4 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07664527, a Phase 4 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is to find out if an Extra Virgin Olive-Oil-based Water (EVOOW) mix, removes more Fluticasone Propionate (FP) from the mouth than Water alone. 2 strengths of the EVOOW mix will be tested, one with equal parts EVOO and Water (50/50) and one with 3 parts EVOO and 1 part Water (75/25). Removing more FP deposits may help decrease the risk for obstructive sleep apnea (OSA), candidiasis (thrush), and speech and swallow dysfunction. Participants will be on study for up to 3 weeks.
Primary Outcome
The primary outcome measure is FP concentration in mouthwashes, measured using mass spectrometry. The primary comparison of interest is the treatment-by-group interaction, representing the differential treatment effect (EVOOW vs. Water) between asthma and healthy participants. 3 separate 20ml aliquots will be administered and collected during each of 2 study visits, 7-10 days apart.
Interventions
- DRUG Fluticasone Propionate
- OTHER Water Mouthwash
- OTHER EVOOW Mouthwash
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
What is known before NCT07664527 opens enrollment
NCT07664527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Fluticasone Propionate is the first listed.
NCT07664527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07664527 about?
NCT07664527 is a clinical study titled "Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate". This study is to find out if an Extra Virgin Olive-Oil-based Water (EVOOW) mix, removes more Fluticasone Propionate (FP) from the mouth than Water alone. 2 strengths of the EVOOW mix will be tested, one with equal parts EVOO and Water (50/50) and one with 3 parts EVOO and 1 part Water (75/25). Remov...
What is the current status of trial NCT07664527?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-07. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07664527?
The interventions under investigation include: Fluticasone Propionate (DRUG), Water Mouthwash (OTHER), EVOOW Mouthwash (OTHER).
Who is sponsoring clinical trial NCT07664527?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07664527's enrollment target sits among peer trials
20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia